In lung cancers, IL-34 triggers activation of CCAAT/enhancer-binding protein β via AKT-mediated pathway with the downstream effect of enhancing the pro-tumorigenic and immunosuppressive functions of TAMs and consequently promoting the survival of chemoresistant cancer cells [36]. Here, IL34 is linked to lung carcinoma.